These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 35152768)

  • 21. ELLIPSE Study: a Phase 1 study evaluating the tolerance of bevacizumab nasal spray in the treatment of epistaxis in hereditary hemorrhagic telangiectasia.
    Dupuis-Girod S; Ambrun A; Decullier E; Samson G; Roux A; Fargeton AE; Rioufol C; Schwiertz V; Disant F; Chapuis F; Donazzolo Y; Paintaud G; Edery P; Faure F
    MAbs; 2014; 6(3):794-9. PubMed ID: 24481211
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intravenous bevacizumab for complications of hereditary hemorrhagic telangiectasia: a review of the literature.
    Arizmendez NP; Rudmik L; Poetker DM
    Int Forum Allergy Rhinol; 2015 Nov; 5(11):1042-7. PubMed ID: 26202958
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development and Validation of the Nasal Outcome Score for Epistaxis in Hereditary Hemorrhagic Telangiectasia (NOSE HHT).
    Peterson AM; Kallogjeri D; Spitznagel E; Chakinala MM; Schneider JS; Piccirillo JF
    JAMA Otolaryngol Head Neck Surg; 2020 Nov; 146(11):999-1005. PubMed ID: 33022056
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intranasal bevacizumab in the treatment of HHT -related epistaxis: a systematic review.
    Stokes P; Rimmer J
    Rhinology; 2018 Mar; 56(1):3-10. PubMed ID: 29166422
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intranasal Efudix reduces epistaxis in hereditary hemorrhagic telangiectasia.
    de Jel DVC; Disch FJM; Kroon S; Mager JJ; Verdam FJ
    Angiogenesis; 2020 Aug; 23(3):271-274. PubMed ID: 32112177
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Research progress of bevacizumab in the treatment of refractory epistaxis caused by hereditary hemorrhagic telangiectasia].
    Xu C; Wang HT
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2016 Jun; 51(6):476-9. PubMed ID: 27345893
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New classification of nasal vasculature patterns in hereditary hemorrhagic telangiectasia.
    Mahoney EJ; Shapshay SM
    Am J Rhinol; 2006; 20(1):87-90. PubMed ID: 16539301
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Medical Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia: A Meta-analysis.
    Hsu YP; Hsu CW; Bai CH; Cheng SW; Chen C
    Otolaryngol Head Neck Surg; 2019 Jan; 160(1):22-35. PubMed ID: 30200816
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Medical treatment of epistaxis in hereditary hemorrhagic telangiectasia: an evidence-based review.
    Halderman AA; Ryan MW; Clark C; Sindwani R; Reh DD; Poetker DM; Invernizzi R; Marple BF
    Int Forum Allergy Rhinol; 2018 Jun; 8(6):713-728. PubMed ID: 29393992
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correlation of severity of epistaxis with nasal telangiectasias in hereditary hemorrhagic telangiectasia (HHT) patients.
    Pagella F; Colombo A; Matti E; Giourgos G; Tinelli C; Olivieri C; Danesino C
    Am J Rhinol Allergy; 2009; 23(1):52-8. PubMed ID: 19379613
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical Practice Guideline: Nosebleed (Epistaxis) Executive Summary.
    Tunkel DE; Anne S; Payne SC; Ishman SL; Rosenfeld RM; Abramson PJ; Alikhaani JD; Benoit MM; Bercovitz RS; Brown MD; Chernobilsky B; Feldstein DA; Hackell JM; Holbrook EH; Holdsworth SM; Lin KW; Lind MM; Poetker DM; Riley CA; Schneider JS; Seidman MD; Vadlamudi V; Valdez TA; Nnacheta LC; Monjur TM
    Otolaryngol Head Neck Surg; 2020 Jan; 162(1):8-25. PubMed ID: 31910122
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical Practice Guideline: Nosebleed (Epistaxis).
    Tunkel DE; Anne S; Payne SC; Ishman SL; Rosenfeld RM; Abramson PJ; Alikhaani JD; Benoit MM; Bercovitz RS; Brown MD; Chernobilsky B; Feldstein DA; Hackell JM; Holbrook EH; Holdsworth SM; Lin KW; Lind MM; Poetker DM; Riley CA; Schneider JS; Seidman MD; Vadlamudi V; Valdez TA; Nnacheta LC; Monjur TM
    Otolaryngol Head Neck Surg; 2020 Jan; 162(1_suppl):S1-S38. PubMed ID: 31910111
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hereditary hemorrhagic telangiectasia (HHT): a practical guide to management.
    Hammill AM; Wusik K; Kasthuri RS
    Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):469-477. PubMed ID: 34889398
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intranasal bevacizumab injections improve quality of life in HHT patients.
    Steineger J; Geirdal AØ; Osnes T; Heimdal KR; Dheyauldeen S
    Laryngoscope; 2020 May; 130(5):E284-E288. PubMed ID: 31287573
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A silicone nasal swab for the treatment of severe and recalcitrant epistaxis in hereditary hemorrhagic telangiectasia: an alternative to surgical nostril closure.
    Bruschini L; Seccia V; Dallan I
    Am J Otolaryngol; 2011; 32(4):301-3. PubMed ID: 20719406
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A review on clinical management and pharmacological therapy on hereditary haemorrhagic telangiectasia (HHT).
    Zarrabeitia R; Albiñana V; Salcedo M; Señaris-Gonzalez B; Fernandez-Forcelledo JL; Botella LM
    Curr Vasc Pharmacol; 2010 Jul; 8(4):473-81. PubMed ID: 19485912
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bevacizumab in hereditary hemorrhagic telangiectasia-associated epistaxis: effectiveness of an injection protocol based on the vascular anatomy of the nose.
    Dheyauldeen S; Østertun Geirdal A; Osnes T; Vartdal LS; Dollner R
    Laryngoscope; 2012 Jun; 122(6):1210-4. PubMed ID: 22565282
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influence of temporary nasal occlusion (tNO) on epistaxis frequency in patients with hereditary hemorrhagic telangiectasia (HHT).
    Wirsching KEC; Haubner F; Kühnel TS
    Eur Arch Otorhinolaryngol; 2017 Apr; 274(4):1891-1896. PubMed ID: 28070641
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term efficacy assessment of current treatment options for epistaxis in HHT.
    Dür C; Anschuetz L; Negoias S; Bulut OC; Angelillo-Scherrer A; Caversaccio M
    Eur Arch Otorhinolaryngol; 2021 Nov; 278(11):4321-4328. PubMed ID: 33661356
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pazopanib effective for bevacizumab-unresponsive epistaxis in hereditary hemorrhagic telangiectasia.
    Parambil JG; Woodard TD; Koc ON
    Laryngoscope; 2018 Oct; 128(10):2234-2236. PubMed ID: 29451965
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.